Method of reducing scarring

Abstract

A method for reducing scarring comprises applying into a wound a composition comprising resveratrol. The wound was formed at most one day before the applying, and no part of the skin surface of the wound is more than 3 cm from uninjured skin.

1 . A method for reducing scarring, comprising: applying into a wound, a composition comprising resveratrol,
 wherein the wound was formed at most one day before the applying, and   no part of the skin surface of the wound is more than 3 cm from uninjured skin.   
     
     
         2 . The method of  claim 1 , wherein an amount of resveratrol present in the composition is 10 to 1000 micromoles/liter. 
     
     
         3 - 4 . (canceled) 
     
     
         5 . The method of  claim 1 , wherein the wound was formed at most one hour before the applying. 
     
     
         6 - 8 . (canceled) 
     
     
         9 . The method of  claim 1 , wherein no part of the skin surface of the wound is more than 0.5 cm from uninjured skin. 
     
     
         10 . The method of  claim 1 , wherein the composition is a gel, paste, foam, suspension or thickened solution. 
     
     
         11 . The method of  claim 1 , wherein the composition is a gel or thickened solution. 
     
     
         12 - 20 . (canceled) 
     
     
         21 . A composition for reducing scarring comprising:
 resveratrol, and   at least one member selected from the group consisting of hydroxypropyl methylcellulose, high molecular weight hyaluronic acid, polyethylene glycol, agar, dextrin, pectin, trehalose, xanthan gum, polyoxyethylene alkyl ethers, chitosan, guar gum and sodium alginate,   wherein an amount of resveratrol present in the composition is 10 to 1000 micromoles/liter.   
     
     
         22 . (canceled) 
     
     
         23 . The composition of  claim 21 , wherein an amount of resveratrol present in the composition is 40 to 400 micromoles/liter. 
     
     
         24 . The composition of  claim 21 , wherein an amount of resveratrol present in the composition is 80 to 150 micromoles/liter. 
     
     
         25 - 29 . (canceled) 
     
     
         30 . The composition of  claim 21 , wherein the composition is a gel, paste, foam, suspension or thickened solution. 
     
     
         31 . The composition of  claim 21 , wherein the composition is a gel or thickened solution. 
     
     
         32 . (canceled) 
     
     
         33 . The composition of  claim 21 , wherein the composition further comprises the hydroxypropyl methylcellulose or the high molecular weight hyaluronic acid. 
     
     
         34 . The composition of  claim 21 , wherein the composition comprises the hydroxypropyl methylcellulose. 
     
     
         35 . The composition of  claim 21 , wherein the composition is provided as a unit dosage form. 
     
     
         36 . The composition of  claim 35 , wherein the unit dosage form has a volume of 0.1 to 100 ml. 
     
     
         37 . The composition of  claim 35 , wherein the unit dosage form has a volume of 1 to 50 ml. 
     
     
         38 . The composition of  claim 35 , wherein the unit dosage form has a volume of 5 to 10 ml. 
     
     
         39 . The composition of  claim 35 , wherein the unit dosage form is selected from the group consisting of a prefilled syringe, a pouch, a packet and a tube. 
     
     
         40 . The composition of  claim 21 , wherein the composition further comprises at least one member selected from the group consisting of a SIRT1 activator; a HDAC2 inhibitor; an agent which stimulate the production of EGF, FGF-10 or IGF-1; luteolin; tretinoin; and high molecular weight hyaluronic acid. 
     
     
         41 - 60 . (canceled) 
     
     
         61 . The method of  claim 1 , wherein the wound is an incision.